Krystal Biotech receives ODD from Japanese MHLW for B-VEC

Krystal Biotech announced that the Japan Ministry of Health, Labour and Welfare, MHLW, has granted Orphan Drug Designation, ODD, to beremagene geperpavec-svdt, B-VEC, for the treatment of dystrophic epidermolysis bullosa, DEB. “Receiving ODD is an important step in expediting the development of B-VEC in Japan and underscores the unmet needs of patients with DEB,” said Suma Krishnan, President, Research & Development, Krystal Biotech, Inc. “We look forward to working closely with MHLW to bring this important treatment to patients in Japan as soon as possible.”